Glaukos subsequently advanced a second-generation treatment, Epioxa, through phase III trials. SanaCurrents assigns a pivolat probability Glaukos will submit an NDA for Epioxa in 2022.
Glaukos subsequently advanced a second-generation treatment, Epioxa, through phase III trials. SanaCurrents assigns a pivolat probability Glaukos will submit an NDA for Epioxa in 2022.